Demonstrates strong safety and oral PKData presented November 7, 2019 at PFF Summit, San Antonio, TX Cambridge, MA, November 11, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), for the first time presented clinical data […]

The Capital M Podcast #LifeScienceRevolution: Proximity to Resources with KaloCyte. Listen to part 3 of the Capital M podcast, #LifeScienceRevolution: Proximity to Resources with KaloCyte. In this episode, MTC CEO Martin Rosendale discusses business in Maryland with Elaine E. Hayne, President and CEO of KaloCyte, Inc., a pre-clinical biotech startup developing a synthetic red blood cell substitute. Listen to the […]

First CAR-T to enter clinical development for an autoimmune disease Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential for potency while minimizing risk of toxicity Gaithersburg, MD, November 5, 2019 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company developing cell and gene therapies for cancer and autoimmune diseases, today […]

The growth of the BioHealth Capital Region (BHCR) and its position as a global biohealth cluster is a hot topic of discussion—often filtered through a broad, conceptual lens focused on big-picture trends, GEN publication rankings and widely discussed areas of industry need. The development and growth of the BHCR is also a story that supports the life […]